Summit Therapeutics Inc.
SMMT
Rangering i aksjer
#1720
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Aksjekurs
$15.34
Markedsverdi
$12.24B
Endring (1 dag)
-3.10%
Endring (1 år)
-19.94%
Land
US
Handel Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
Aksjeprishistorikk for Summit Therapeutics Inc. (SMMT)
Høyeste sluttskurs: $16.33 den 2026-10-01
Laveste sluttskurs: $11.32 den 2015-03-01
Laveste sluttskurs: $11.32 den 2015-03-01
Aksjeprishistorikk for Summit Therapeutics Inc. fra 2015 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -6.38% |
| 2025 | -2.36% |
| 2024 | 648.94% |
| 2023 | -27.28% |
| 2022 | -16.52% |
| 2021 | -23.50% |
| 2020 | 244.19% |
| 2019 | 23.13% |
| 2018 | -88.74% |
| 2017 | 19.67% |
| 2016 | -15.67% |
| 2015 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $536.47 | 25.80% |
US
|
|
| $187.21 | 597.24% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $883.47 | 8.51% |
NL
|
